Cronos Group (CRON) and Its Peers Head-To-Head Contrast

Cronos Group (NASDAQ:CRON) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Cronos Group to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cronos Group and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0	1	3	1	3.00
Cronos Group Competitors	7782	13868	25755	1034	2.41

Cronos Group presently has a consensus target price of $2.30, indicating a potential downside of 38.01%. As a group, “Pharmaceuticals” companies have a potential upside of 28.88%. Given Cronos Group’s rivals higher probable upside, analysts clearly believe Cronos Group has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Cronos Group and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cronos Group	$146.59 million	-$9.45 million	18.55
Cronos Group Competitors	$5.29 billion	$3.19 billion	548.18

Cronos Group’s rivals have higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Cronos Group has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Cronos Group’s rivals have a beta of -4.10, meaning that their average stock price is 510% less volatile than the S&P 500.

Institutional and Insider Ownership

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.8% of Cronos Group shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Cronos Group and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Cronos Group Competitors	-2,381.29%	-218.58%	-15.77%

Summary

Cronos Group beats its rivals on 7 of the 13 factors compared.

Cronos Group Company Profile

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.